Toxic risk of stereotactic body radiotherapy and concurrent helical tomotherapy followed by erlotinib for non-small-cell lung cancer treatment - case report
Journal
BMC Cancer
Journal Volume
10
Pages
696
Date Issued
2010
Author(s)
Hsieh C.-H.
Chang H.-T.
Lin S.-C.
Chen Y.-J.
Hsieh Y.-P.
Chen C.-A.
Chong N.-S.
Lin S.L.
Chen C.-Y.
Shueng P.-W.
Abstract
Background: Stereotactic body radiation therapy (SBRT) applied by helical tomotherapy (HT) is feasible for lung cancer in clinical. Using SBRT concurrently with erlotinib for non-small cell lung cancer (NSCLC) is not reported previously.Case Presentation: A 77-year-old man with stage III NSCLC, received erlotinib 150 mg/day, combined with image-guided SBRT via HT. A total tumor dose of 54 Gy/9 fractions was delivered to the tumor bed. The tumor responded dramatically and the combined regimen was well tolerated. After concurrent erlotinib-SBRT, erlotinib was continued as maintenance therapy. The patient developed dyspnea three months after the combined therapy and radiation pneumonitis with interstitial lung disease was suspected.Conclusions: Combination SBRT, HT, and erlotinib therapy provided effective anti-tumor results. Nonetheless, the potential risks of enhanced adverse effects between radiation and erlotinib should be monitored closely, especially when SBRT is part of the regimen. ? 2010 Hsieh et al; licensee BioMed Central Ltd.
SDGs
Other Subjects
carcinoembryonic antigen; erlotinib; antineoplastic agent; EGFR protein, human; epidermal growth factor receptor; erlotinib; protein kinase inhibitor; quinazoline derivative; aged; article; case report; computer assisted tomography; dyspnea; human; interstitial lung disease; lung non small cell cancer; lung volume; maintenance therapy; male; multimodality cancer therapy; radiation pneumonia; stereotactic body radiation therapy; therapy effect; tomotherapy; tumor volume; adjuvant chemotherapy; adjuvant therapy; cancer staging; computer assisted radiotherapy; drug antagonism; dyspnea; enzymology; fatality; interstitial lung disease; lung non small cell cancer; lung tumor; radiation dose fractionation; radiation pneumonia; radiography; radiosurgery; time; treatment outcome; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Dose Fractionation; Dyspnea; Fatal Outcome; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Radiation Pneumonitis; Radiosurgery; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Receptor, Epidermal Growth Factor; Time Factors; Tomography, X-Ray Computed; Treatment Outcome
Type
journal article